3037124-22-1
3037124-22-1
Chemical Structure
Besufetamig
Synonym(s): ONO-4685
- CAS No.: 3037124-22-1
- Formula:N/A
- Molecular Weight:(146.01 kDa)
SMILES: [Besufetamig]
Biological Activity: Besufetamig (ONO-4685) is a bispecific antibody that simultaneously targets PD-1 and CD3. Besufetamig achieves CTL-mediated tumor cell killing. Besufetamig inhibits tumor growth in PBMC mouse xenograft models of PD-1-expressing T-cell lymphoma/leukemia[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Besufetamig | 99.98% | Besufetamig (ONO-4685) is a bispecific antibody that simultaneously targets PD-1 and CD3. Besufetamig achieves CTL-mediated tumor cell killing. Besufetamig inhibits tumor growth in PBMC mouse xenograft models of PD-1-expressing T-cell lymphoma/leukemia. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Naho Tateshit, et al. Abstract 7324: ONO-4685: A novel PD-1/CD3 bispecifc T-cell engager (TCE) for the treatment of T-cell malignancies. Cancer Res (2025) 85 (8_Supplement_1): 7324.
- [2]. Case KB, et al. Advances in Novel Systemic Therapies for the Management of Cutaneous T Cell Lymphoma (CTCL). Current hematologic malignancy reports. 2025 Jan 13;20(1):5.
- [3]. Xue E, et al. Trial Watch - bispecific T cell engagers and higher-order multispecific immunotherapeutics. Oncoimmunology. 2026 Dec 31;15(1):2632421.
